Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies

Imatinib (Gleevec/STI-571/CGP57148B, Novartis) is a small-molecule, tyrosine kinase inhibitor developed to target BCR-ABL, c-Kit, and PDGF-R. Through inhibition of these oncogenic kinases, imatinib is effective in the treatment of BCR–ABL—positive leukemia, gastrointestinal stromal tumor, and hypere...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgess, Michael R., Sawyers, Charles L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2006
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917346/
https://www.ncbi.nlm.nih.gov/pubmed/16906325
http://dx.doi.org/10.1100/tsw.2006.184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917346/
https://www.ncbi.nlm.nih.gov/pubmed/16906325
http://dx.doi.org/10.1100/tsw.2006.184

Ejemplares similares